ArticleYonsei medical journal2015
Risk factors for mortality in patients with Serratia marcescens bacteremia.
Article in Yonsei medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 67 citations in OpenAlex.
- Serratia Bacteraemia in the North Denmark Region: A Population-Based Study (2010-2024).APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Clinical and Genomic Characterization of Serratia Bloodstream Infections.CMI communications · 2025Article
- Article
- Serratia marcescens as an Uncommon Cause of Infection Following Craniectomy: A Case Report and Literature Review.Cureus · 2025Article
- Serratia marcescens and its role in Pink breast milk and upper GI bleeding in an infant: a Tanzanian case report.BMC infectious diseases · 2025Article
- The Biphasic Effect of Lipopolysaccharide on Membrane Potential.Membranes · 2025Article
- Metatranscriptomic insights into the dengue patient blood microbiome: Enhanced microbial diversity and metabolic activity in severe patients.PLoS neglected tropical diseases · 2024Article
- Article
- Cultivation and sequencing-free protocol foriScience · 2024Article
- Antimicrobial Resistance Pattern, Predisposing Factors, and Outcome of Serratia Infection in Patients Treated at a Secondary-Care Hospital in Oman: A 5-Year Retrospective Study.Advanced biomedical research · 2024Article
- The Effects of Doxapram Blocking the Response of Gram-Negative Bacterial Toxin (LPS) at Glutamatergic Synapses.Biology · 2023Article
- Diminishing the Pathogenesis of the Food-Borne PathogenBiology · 2023Article
- Outbreak ofAdvances in medicine · 2023Article
- New insights into the antibacterial mode of action of quercetin against uropathogen Serratia marcescens in-vivo and in-vitro.Scientific reports · 2022Article
- Evaluation of the whole proteome to design a novel mRNA-based vaccine against multidrug-resistantFrontiers in microbiology · 2022Article
- A Systematic Immuno-Informatic Approach to Design a Multiepitope-Based Vaccine Against Emerging Multiple Drug ResistantFrontiers in immunology · 2022Article
- Remedial Aspect of Zinc Oxide Nanoparticles AgainstFrontiers in pharmacology · 2022Article
- Article
- Antibacterial Activity of Biosynthesized Selenium Nanoparticles Using Extracts ofMolecules (Basel, Switzerland) · 2021Article
- Serrating through vascular access catheters: a great masquerader with severe systemic manifestations.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOver the last 30 years, Serratia marcescens (S. marcescens) has emerged as an important pathogen, and a common cause of nosocomial infections. The aim of this study was to identify risk factors associated with mortality in patients with S. marcescens bacteremia. MATERIALS AND
methodsWe performed a retrospective cohort study of 98 patients who had one or more blood cultures positive for S. marcescens between January 2006 and December 2012 in a tertiary care hospital in Seoul, South Korea. Multiple risk factors were compared with association with 28-day all-cause mortality.
resultsThe 28-day mortality was 22.4% (22/98 episodes). In a univariate analysis, the onset of bacteremia during the intensive care unit stay (p=0.020), serum albumin level (p=0.011), serum C-reactive protein level (p=0.041), presence of indwelling urinary catheter (p=0.023), and Sequential Oran Failure Assessment (SOFA) score at the onset of bacteremia (p<0.001) were significantly different between patients in the fatal and non-fatal groups. In a multivariate analysis, lower serum albumin level and an elevated SOFA score were independently associated with 28-day mortality [adjusted odds ratio (OR) 0.206, 95% confidential interval (CI) 0.044-0.960, p=0.040, and adjusted OR 1.474, 95% CI 1.200-1.810, p<0.001, respectively].
conclusionLower serum albumin level and an elevated SOFA score were significantly associated with adverse outcomes in patients with S. marcescens bacteremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.